Minerva Neurosciences (NERV) Operating Leases (2019 - 2020)
Minerva Neurosciences (NERV) reported Operating Leases of $16288.0 for Q2 2020, down 91.9% on a YoY basis from $201066.0 in Q3 2019, and down 74.69% quarter-over-quarter from $64350.0 in Q1 2020.
Minerva Neurosciences (NERV) Operating Leases (2019 - 2020) Analysis & Trends
Minerva Neurosciences has reported Operating Leases for 2 years, with the latest figure at $16288.0 in Q2 2020.
- For the quarter ending Q2 2020, Operating Leases fell 91.9% year-over-year to $16288.0; the trailing twelve-month figure through Jun 2020 stood at $16288.0 (down 91.9% YoY), and the FY2019 full-year result was $111229.0, changed N/A from the prior year.
- Operating Leases for Q2 2020 stood at $16288.0, down from $64350.0 in the prior quarter.
- The five-year high for Operating Leases was $243115.0 in Q1 2019, with the low at $16288.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Minerva Neurosciences | 197.55 Mn | 197.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 16,288.00 |
| Mar 31, 2020 | 64,350.00 |
| Dec 31, 2019 | 111,229.00 |
| Sep 30, 2019 | 156,956.00 |
| Jun 30, 2019 | 201,066.00 |
| Mar 31, 2019 | 243,115.00 |